SCHEMBL1845320

SCHEMBL1845320

CCN1C(=O)C(C)c2cnc(N3CCCCC3)nc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
LMNA P02545 1/20 0.39
CASP1 P29466 1/20 0.39
TSHR P16473 1/20 0.39
ALDH1A1 P00352 6/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
GBA1 P04062 1/20 0.34
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
MAPT P10636 2/20 0.33
CYP1A2 P05177 2/20 0.32
HSD17B10 Q99714 2/20 0.32
GLA P06280 1/20 0.32
TLR9 Q9NR96 1/20 0.32
TLR7 Q9NYK1 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1922986 0.83 POLB (0.42) POLBSMN1; SMN2LMNACASP1TSHR
SCHEMBL1847423 0.74 POLB (0.41) POLBSMN1; SMN2LMNACASP1TSHR
SCHEMBL1849696 0.70 ALDH1A1 (0.46) SMN1; SMN2LMNACASP1TSHRALDH1A1
SCHEMBL1846068 0.69 SMN1; SMN2 (0.42) POLBSMN1; SMN2LMNACASP1TSHR
SCHEMBL1845316 0.67 POLB (0.39) POLBSMN1; SMN2LMNACASP1TSHR
SCHEMBL2346641 0.66 PLK1 (0.65)
SCHEMBL2027430 0.66 PLK1 (0.65)
SCHEMBL8809105 0.66 HTT (0.51) SMN1; SMN2LMNACASP1TSHRALDH1A1
SCHEMBL1845750 0.65 LMNA (0.41) POLBSMN1; SMN2LMNACASP1TSHR
SCHEMBL2026743 0.65 PLK1 (0.66)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2324023-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES UNIVERSITY OF CENTRAL FLORIDA (US) 2011-05-25 EP claimed
WO-2009070164-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES UNIVERSITY OF CENTRAL FLORIDA (US) 2009-06-04 WO claimed
US-20080124306-A1 Vigor Enhancement Via Administration of Pyrimidine Derivatives UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2008-05-29 US claimed
US-20230302000-A1 COMBINATION DRUG TREATMENT TO INCREASE NEUROGENESIS FOR NEUROLOGICAL DISORDERS Progenicyte Therapeutics, Inc. (US) 2023-09-28 US disclosed
US-20210046079-A1 COMBINATION THERAPY TO IMPROVE BRAIN FUNCTION OR PROMOTE NEUROGENESIS FOR TREATING NEURODEGENERATIVE CONDITIONS UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2021-02-18 US disclosed
US-20200246334-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2020-08-06 US disclosed
US-20190167674-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2019-06-06 US disclosed
US-20180092913-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2018-04-05 US disclosed
EP-2326330-B1 COMPOSITIONS FOR TREATING OR DELAYING THE ONSET OF HAIR LOSS UNIV CENTRAL FLORIDA RES FOUND (US) 2015-01-07 EP disclosed
US-8791128-B2 Compositions for treating or delaying the onset of hair loss UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) 2014-07-29 US disclosed
US-20110190320-A1 Compositions for Treating or Delaying the Onset of Hair Loss UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2011-08-04 US disclosed
EP-2324023-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES UNIVERSITY OF CENTRAL FLORIDA (US) 2011-05-25 EP disclosed
WO-2010087527-A1 ULTRAVIOLET ABSORBERS, AND PHARMACEUTICAL COMPOSITIONS AND COSMETICS CONTAINING PYRIMIDINE COMPOUNDS FOR UV PROTECTION AWAYA AKIRA (JP) 2010-08-05 WO disclosed
WO-2010033576-A1 COMPOSITIONS FOR TREATING OR DELAYING THE ONSET OF HAIR LOSS UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) 2010-03-25 WO disclosed
WO-2009070164-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES UNIVERSITY OF CENTRAL FLORIDA (US) 2009-06-04 WO disclosed
US-20080124306-A1 Vigor Enhancement Via Administration of Pyrimidine Derivatives UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2008-05-29 US disclosed
EP-1890673-A1 USE OF PYRIMIDINE DERIVATIVES FOR COSMETIC PURPOSES DSMIP Assets B.V. (NL) 2008-02-27 EP disclosed
WO-2006133876-A1 USE OF PYRIMIDINE DERIVATIVES FOR COSMETIC PURPOSES DSM IP ASSETS B.V. (NL) 2006-12-21 WO disclosed
US-5976523-A PIPERIDINE- OR PIPERAZINE-SUBSTITUTED PYRROLOPYRIMIDINES MITSUI PHARMACEUTICALS, INC. (JP) 1999-11-02 US disclosed
EP-0743066-A2 Wound-healing agent MITSUI PHARMACEUTICALS, INC. (JP) 1996-11-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080124306-A1 Vigor Enhancement Via Administration of Pyrimidine Derivatives TYMP, SLC18A3, SLC18A2 POLB 943/4885SMN1; SMN2 205/4885LMNA 4740/4885
US-20190167674-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES TYMP, SLC18A3, SLC18A2 POLB 943/4885SMN1; SMN2 205/4885LMNA 4740/4885
US-20210046079-A1 COMBINATION THERAPY TO IMPROVE BRAIN FUNCTION OR PROMOTE NEUROGENESIS FOR TREATING NEURODEGENERATIVE CONDITIONS PSEN1, PSEN2, NES POLB 3126/4885SMN1; SMN2 80/4885LMNA 3338/4885
US-20110190320-A1 Compositions for Treating or Delaying the Onset of Hair Loss SHBG, CYP19A1, TYMP POLB 58/4885SMN1; SMN2 4808/4885LMNA 1858/4885
US-20180092913-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES TYMP, SLC18A3, SLC18A2 POLB 943/4885SMN1; SMN2 205/4885LMNA 4740/4885
US-20230302000-A1 COMBINATION DRUG TREATMENT TO INCREASE NEUROGENESIS FOR NEUROLOGICAL DISORDERS NES, PSEN1, PSEN2 POLB 3750/4885SMN1; SMN2 78/4885LMNA 2159/4885
US-20200246334-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES TYMP, SLC18A3, SLC18A2 POLB 943/4885SMN1; SMN2 205/4885LMNA 4740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.